349 reports of this reaction
3.4% of all IRBESARTAN AND HYDROCHLOROTHIAZIDE reports
#1 most reported adverse reaction
NAUSEA is the #1 most commonly reported adverse reaction for IRBESARTAN AND HYDROCHLOROTHIAZIDE, manufactured by Sanofi-Aventis U.S. LLC. There are 349 FDA adverse event reports linking IRBESARTAN AND HYDROCHLOROTHIAZIDE to NAUSEA. This represents approximately 3.4% of all 10,188 adverse event reports for this drug.
Patients taking IRBESARTAN AND HYDROCHLOROTHIAZIDE who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is moderately reported among IRBESARTAN AND HYDROCHLOROTHIAZIDE users, representing a notable but not dominant share of adverse events.
In addition to nausea, the following adverse reactions have been reported for IRBESARTAN AND HYDROCHLOROTHIAZIDE:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 349 FDA reports for IRBESARTAN AND HYDROCHLOROTHIAZIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 3.4% of all adverse event reports for IRBESARTAN AND HYDROCHLOROTHIAZIDE, making it one of the most commonly reported side effect.
If you experience nausea while taking IRBESARTAN AND HYDROCHLOROTHIAZIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.